Vitae Pharmaceuticals Company Profile (NASDAQ:VTAE)

About Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals logoVitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VTAE
  • CUSIP: N/A
  • Web: vitaepharma.com/
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.35
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -318,350.20%
  • Return on Equity: -53.70%
  • Return on Assets: -49.85%
Debt:
  • Current Ratio: 12.83%
  • Quick Ratio: 12.83%
Misc:
  • Beta: 0.62
 

Frequently Asked Questions for Vitae Pharmaceuticals (NASDAQ:VTAE)

What is Vitae Pharmaceuticals' stock symbol?

Vitae Pharmaceuticals trades on the NASDAQ under the ticker symbol "VTAE."

How were Vitae Pharmaceuticals' earnings last quarter?

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) released its earnings results on Wednesday, August, 3rd. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.05. Vitae Pharmaceuticals had a negative net margin of 318,350.20% and a negative return on equity of 53.70%. The firm's revenue was down 98.0% on a year-over-year basis. During the same period last year, the business posted ($0.45) earnings per share. View Vitae Pharmaceuticals' Earnings History.

Who are some of Vitae Pharmaceuticals' key competitors?

How do I buy Vitae Pharmaceuticals stock?

Shares of Vitae Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vitae Pharmaceuticals' stock price today?

One share of Vitae Pharmaceuticals stock can currently be purchased for approximately $21.00.


MarketBeat Community Rating for Vitae Pharmaceuticals (NASDAQ VTAE)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  204
MarketBeat's community ratings are surveys of what our community members think about Vitae Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vitae Pharmaceuticals (NASDAQ:VTAE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Price Target History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Analysts' Ratings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
9/15/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$17.00 -> $21.00N/AView Rating Details
9/14/2016WedbushDowngradeOutperform -> Neutral$21.00 -> $23.00N/AView Rating Details
9/14/2016Stifel NicolausDowngradeBuy -> Hold$21.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
8/4/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Earnings by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Earnings History by Quarter for Vitae Pharmaceuticals (NASDAQ VTAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q2($0.41)($0.36)$0.05 millionViewListenView Earnings Details
5/10/2016Q1($0.51)($0.44)$0.09 million$0.05 millionViewListenView Earnings Details
3/3/2016Q415($0.62)($0.52)$0.14 million$0.09 millionViewListenView Earnings Details
11/5/2015Q315($0.48)($0.60)$0.18 million$0.18 millionViewListenView Earnings Details
8/4/2015Q215($0.45)($0.45)$0.09 million$0.16 millionViewListenView Earnings Details
5/12/2015Q115($0.33)($0.47)$0.16 million$0.15 millionViewListenView Earnings Details
3/31/2015Q414($0.45)($0.40)$0.19 million$0.16 millionViewListenView Earnings Details
11/12/2014Q3($0.13)($1.03)$6.39 million$6.18 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vitae Pharmaceuticals (NASDAQ:VTAE)
2017 EPS Consensus Estimate: ($1.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Insider Ownership Percentage: 14.80%
Institutional Ownership Percentage: 72.58%
Insider Trades by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Institutional Ownership by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Insider Trades by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2016Adage Capital Partners Gp, L.LMajor ShareholderSell1,025,000$20.85$21,371,250.00View SEC Filing  
9/14/2016Jeffrey S HatfieldCEOSell50,000$20.81$1,040,500.00View SEC Filing  
3/21/2016Donald J Hayden JrDirectorSell16,130$7.42$119,684.60View SEC Filing  
12/29/2015Donald J. Hayden, Jr.DirectorSell16,130$18.00$290,340.00View SEC Filing  
12/23/2015Jeffrey S. HatfieldCEOSell22,524$17.00$382,908.00View SEC Filing  
9/21/2015Donald J. Hayden, Jr.DirectorSell16,130$17.00$274,210.00View SEC Filing  
9/29/2014Peter BarrettDirectorBuy37,500$8.00$300,000.00View SEC Filing  
9/29/2014Venrock Management Iii LlcMajor ShareholderBuy772,333$8.00$6,178,664.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vitae Pharmaceuticals (NASDAQ:VTAE)
Latest Headlines for Vitae Pharmaceuticals (NASDAQ:VTAE)
Source:
DateHeadline
americanbankingnews.com logoHead to Head Review: Kamada (KMDA) vs. Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - October 14 at 6:20 PM
americanbankingnews.com logoComparing Anika Therapeutics (ANIK) & Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - October 3 at 8:22 PM
americanbankingnews.com logoVitae Pharmaceuticals (VTAE) and Its Peers Critical Review
www.americanbankingnews.com - September 20 at 4:12 PM
americanbankingnews.com logoReviewing VIVUS (VVUS) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - September 19 at 12:48 AM
americanbankingnews.com logoHead to Head Comparison: Vitae Pharmaceuticals (VTAE) & Its Rivals
www.americanbankingnews.com - September 18 at 4:30 PM
americanbankingnews.com logoContrasting Onconova Therapeutics (ONTX) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - September 11 at 8:36 PM
americanbankingnews.com logoFinancial Analysis: Vitae Pharmaceuticals (VTAE) versus Vericel Corporation (VCEL)
www.americanbankingnews.com - August 14 at 4:31 PM
americanbankingnews.com logoCritical Survey: Catalyst Biosciences (CBIO) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - August 7 at 10:08 PM
finance.yahoo.com logoAmgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest
finance.yahoo.com - July 30 at 7:17 AM
finance.yahoo.com logo6 Best Performing Drug Stocks of September
finance.yahoo.com - July 30 at 7:17 AM
seekingalpha.com logoAllergan - Waiting For Pipeline Catalysts
seekingalpha.com - June 29 at 3:22 PM
thestreet.com logoAllergan Shifts Strategy to Focus on Growth - TheStreet.com
www.thestreet.com - January 11 at 3:32 PM
thestreet.com logoAllergan to Veer Toward Accretive M&A - TheStreet.com
www.thestreet.com - January 10 at 9:06 PM
seekingalpha.com logoAllergan: You Can't Be Negative On This One
seekingalpha.com - December 21 at 3:31 PM
seekingalpha.com logo4 Reasons To Buy Allergan
seekingalpha.com - November 28 at 10:38 AM
bizjournals.com logo$690M done deal: Allergan completes Vitae acquisition
www.bizjournals.com - November 11 at 8:02 PM
biz.yahoo.com logoVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisit
biz.yahoo.com - October 25 at 8:07 PM
rttnews.com logoAllergan, Vitae Pharma Announce Expiration Of HSR Waiting Period - Quick Facts
www.rttnews.com - October 17 at 7:53 PM
prnewswire.com logoVITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces ... - PR Newswire (press release)
www.prnewswire.com - September 25 at 6:58 AM
thestreet.com logoAllergan's Vitae buy could spark more interest in Kadmon
www.thestreet.com - September 23 at 6:49 AM
benzinga.com logoAllergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma - Benzinga
www.benzinga.com - September 21 at 11:53 AM

Social

Chart

Vitae Pharmaceuticals (VTAE) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.